Novo Nordisk: new findings in type-2 diabetes.
(CercleFinance.com) - Novo Nordisk said a trial showed that people with type-2 diabetes who avoid severe hypoglycaemia have a reduced risk of death.
The Danish drugmaker today announced new analyses from a multinational, double-blinded trial showing that people with type-2 diabetes who experience low blood sugar levels are at a greater risk of death.
The risk was four-fold higher 15 days after an event and two and a half-fold higher anytime following an episode of severe hypoglycaemia, the firm said.
In addition, results also showed that daily fluctuations in blood sugar levels in people with type-2 diabetes are associated with a higher risk of death.
In the trial, Novo Nordisk's Tresiba has reduced the rate of severe hypoglycaemia by 40% and the rate of nocturnal severe hypoglycaemia by 53% compared to insulin glargine in people with type-2 diabetes.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The Danish drugmaker today announced new analyses from a multinational, double-blinded trial showing that people with type-2 diabetes who experience low blood sugar levels are at a greater risk of death.
The risk was four-fold higher 15 days after an event and two and a half-fold higher anytime following an episode of severe hypoglycaemia, the firm said.
In addition, results also showed that daily fluctuations in blood sugar levels in people with type-2 diabetes are associated with a higher risk of death.
In the trial, Novo Nordisk's Tresiba has reduced the rate of severe hypoglycaemia by 40% and the rate of nocturnal severe hypoglycaemia by 53% compared to insulin glargine in people with type-2 diabetes.
Copyright (c) 2017 CercleFinance.com. All rights reserved.